LATE-BREAKING ABSTRACT: Safety and tolerability of once-daily tiotropium Respimat® add-on therapy in children with moderate symptomatic asthma Source: International Congress 2016 – Living with asthma around the globe Year: 2016
Once-daily tiotropium Respimat add-on to at least ICS in adult patients with symptomatic asthma: Pooled safety analysis Source: International Congress 2014 – Asthma and COPD management Year: 2014
Efficacy of tiotropium Respimat® in adults with moderate asthma, by baseline LTRA use Source: International Congress 2015 – Modulating the immune system in COPD and asthma Year: 2015
Add-on effects of long-acting beta2 -agonists salmeterol inhaler vs tulobuterol patch in adult patients with mild-to-moderate asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Safety and tolerability of high-dose formoterol via aerolizer and salbutamol via MDI in patients with mild-to-moderate COPD Source: Eur Respir J 2003; 22: Suppl. 45, 285s Year: 2003
Comparison of the pharmacokinetics and pharmacodynamics of once daily tiotropium Respimat® and tiotropium HandiHaler® in COPD patients Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013
Efficacy of salmeterol/fluticasone pMDI versus DPI in patients with asthma Source: Eur Respir J 2006; 28: Suppl. 50, 499s Year: 2006
Efficacy and safety of new formulation of fluticasone propionate/salmeterol delivered via a HFA pMDI inhaler in patients with asthma Source: Virtual Congress 2020 – Asthma inhalers: devices and adherence studies Year: 2020
Device preference and efficacy of formoterol aerolizer and salbutamol MDI in children with asthma Source: Eur Respir J 2003; 22: Suppl. 45, 134s Year: 2003
24-h efficacy and pharmacokinetics of tiotropium Respimat® 5 μg in patients with asthma Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015
Once-daily tiotropium respimat add-on to ICS±LABA improves control across asthma severities Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014
Efficacy of salmeterol/fluticasone propionate combination administered via Diskus inhaler in children with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 429s Year: 2002
1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014
Safety of as-needed formoterol in asthma patients on different maintenance long-acting ß2-agonists Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021
Efficacy and tolerability of formoterol Turbuhaler in 6–11 year old children with asthma, not adequately controlled with inhaled corticosteroids Source: Eur Respir J 2002; 20: Suppl. 38, 430s Year: 2002
Once-daily tiotropium and olodaterol fixed-dose combination via the respimat improves outcomes vs mono-components in COPD in two 1-year studies Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014
Comparison of indacaterol with tiotropium or once-daily dual long-acting bronchodilator therapy with roflumilast for severe COPD Source: International Congress 2014 – Markers Year: 2014
Safety of tiotropium and olodaterol fixed-dose combination for COPD in patients on β-blockers Source: International Congress 2015 – New data on established treatments for COPD Year: 2015
Efficacy and safety of budesonide/formoterol comparing with budesonide and theophylline in Japanese adult patients with asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008
Effectiveness and safety of fluticasone propionate/salmeterol 250/50mcg administered once daily to patients with persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 309s Year: 2004